Atrion logo

ATRI - Atrion Share Price

$734 25.5  3.6%

Last Trade - 15/01/21

Mid Cap
Market Cap £946.8m
Enterprise Value £915.6m
Revenue £109.5m
Position in Universe 2418th / 6543
Unlock ATRI Revenue
Relative Strength (%)
1m +9.63%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.32%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
140.8 145.7 143.5 146.6 152.4 155.1 +2.0%
+6.8 +9.9 -4.0 +20.2 +3.3 +7.0
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AtrionCorporation revenues decreased 4% to $115.3M. Net incomedecreased 14% to $24.7M. Revenues reflect Cardiovascularsegment decrease of 17% to $37M, Opthalmology segmentdecrease of 47% to $3M, United States segment decrease of14% to $65.6M. Net income also reflects General andadministrative increase of 5% to $13.1M (expense), Interestand dividend income decrease of 34% to $1.1M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ATRI
Graphical History


ATRI Revenue Unlock ATRI Revenue

Net Income

ATRI Net Income Unlock ATRI Revenue

Normalised EPS

ATRI Normalised EPS Unlock ATRI Revenue

PE Ratio Range

ATRI PE Ratio Range Unlock ATRI Revenue

Dividend Yield Range

ATRI Dividend Yield Range Unlock ATRI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATRI EPS Forecasts Unlock ATRI Revenue
Profile Summary

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated December 30, 1996
Public Since December 13, 1995
No. of Shareholders: 8,200
No. of Employees: 616
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 1,828,953
Free Float (0.0%)
Eligible for
ATRI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ATRI
Upcoming Events for ATRI
Wednesday 24th February, 2021 Estimate
Q4 2020 Atrion Corp Earnings Release
Wednesday 5th May, 2021 Estimate
Q1 2021 Atrion Corp Earnings Release
Friday 21st May, 2021 Estimate
Atrion Corp Annual Shareholders Meeting
Frequently Asked Questions for Atrion
What is the Atrion share price?

As of 15/01/21, shares in Atrion are trading at $734, giving the company a market capitalisation of £946.8m. This share price information is delayed by 15 minutes.

How has the Atrion share price performed this year?

Shares in Atrion are currently trading at $734 and the price has moved by 1.22% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atrion price has moved by -11.88% over the past year.

What are the analyst and broker recommendations for Atrion?

Of the analysts with advisory recommendations for Atrion, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Atrion is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Atrion next release its financial results?

Atrion is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Atrion dividend yield?

The Atrion dividend yield is 0.9% based on the trailing twelve month period.

Does Atrion pay a dividend?

Last year, Atrion paid a total dividend of 6.4, and it currently has a trailing dividend yield of 0.9%. Looking ahead, Atrion has not announced an ex-dividend date yet.

When does Atrion next pay dividends?

Atrion has yet to annouce their ex-dividend date. The historic dividend yield on Atrion shares is currently 0.9%.

How do I buy Atrion shares?

To buy shares in Atrion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Atrion?

Shares in Atrion are currently trading at $734, giving the company a market capitalisation of £946.8m.

Where are Atrion shares listed? Where are Atrion shares listed?

Here are the trading details for Atrion:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ATRI
What kind of share is Atrion?

Based on an overall assessment of its quality, value and momentum, Atrion is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Atrion share price forecast 2021?

Shares in Atrion are currently priced at $734. At that level they are trading at 57.66% premium to the analyst consensus target price of 0.00.

How can I tell whether the Atrion share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atrion. Over the past six months, the relative strength of its shares against the market has been -9.37%. At the current price of $734, shares in Atrion are trading at 10.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Atrion PE Ratio?

The Atrion PE ratio based on its reported earnings over the past 12 months is 39.95. The shares are currently trading at $734.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Atrion?

Atrion's management team is headed by:

Emile Battat - CHM
Hugh Morgan - IND
John Stupp - IND
Jeffery Strickland - CFO
Ronald Spaulding - LED
David Battat - CEO
Preston Athey - IND
Who are the major shareholders of Atrion?

Here are the top five shareholders of Atrion based on the size of their shareholding:

Kayne Anderson Rudnick Investment Management, LLC Investment Advisor
Percentage owned: 10.66% (195k shares)
Neuberger Berman, LLC Investment Advisor/Hedge Fund
Percentage owned: 9.15% (167k shares)
Battat (Emile A) Individual Investor
Percentage owned: 8.13% (149k shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 7.92% (145k shares)
Stupp (John P Jr) Individual Investor
Percentage owned: 7.7% (141k shares)
Similar to ATRI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.